An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth A Buy Here?
vTv Therapeutics is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials.
Short Squeezes Are Brewing
When someone buys thousands of call contracts, market makers have to hedge by purchasing stock. That buying pressure forces shorts to cover, creating a feedback loop that can send prices soaring.
Market Talk - Monday, Jan. 5
The oil markets had a mixed day today.
Dow Notches Record Close With Help From Chevron
The Dow rose 595 points to secure a record close, earlier jumping above 49,000 for the first time ever.
